Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||70%|
|1 Day Vol Adjusted Return||-0.9|
|1 Month Vol Adjusted Return||-0.3|
|3 Month Vol Adjusted Return||5.7|
|6 Month Vol Adjusted Return||6.4|
|20 Days SMA Price ZScore||-1.1|
|50 Days SMA Price ZScore||-0.1|
|12 -26 Days PPO||1.3|
|1 Month Average Short Volume Ratio||43.9|
|1 Day Volume Change ZScore||-0.2|
|1 Month Daily Vol||4.7|
On Friday, February 26, Amneal Pharmaceuticals (NYSE:AMRX) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Ba...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") today announced that its management team will virtually attend the following investor conferences:
AMRX vs. CORT: Which Stock Is the Better Value Option?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Does the February share price for Amneal Pharmaceuticals, Inc. ( NYSE:AMRX ) reflect what it's really worth? Today, we...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2021.
AMRX vs. PCRX: Which Stock Is the Better Value Option?
Amneal Pharmaceuticals, Inc. (the "Company") (NYSE:AMRX) and Kashiv BioSciences LLC ("Kashiv") today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC ("Amneal"), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC ("Kashiv Specialty"), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.